Mar. 28 at 4:12 PM
$NEXI Digging the pivot to AIM INJ platform. Preclinical work looks promising. Watching closely for IND filing and potential breakthrough in T-cell therapies. Small position for now. an honest look at company progress: https://beyondspx.com/article/neximmune-inc-nexi-pioneering-a-novel-approach-to-immunotherapy